Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 15, 2007

Dowpharma Licenses Pfenex Expression Technology to Biovel Life Sciences

  • Dowpharma  licensed its Pfenex Expression Technology™ to India-based Biovel Life Sciences. The agreement grants Biovel rights to employ the Pseudomonas fluorescense-based technology for the production of human growth hormone (HGH), a biosimilar product. 

    Dowpharma says it has already developed a high-yield production strain and process for the production of HGH and will prepare and transfer to Biovel a research cell bank and the production process. The agreement provides for an upfront technology access fee, maintenance and milestone fees, as well as royalties on product sales.

  • You’re all set! Thank you for subscribing to GEN Highlights.